Exact Sciences Corp EXAS Stock Price Today, Quote, Latest Discussions, Interactive Chart and News

exas stock price today

And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. EXAS’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Morningstar analysts hand-select direct competitors or comparable companies to

provide context on the strength and durability of EXAS’s

competitive advantage. Exact Sciences’ approach in multi-cancer early detection (MCED) confirmed in first-ever, long-term, follow-up data from an MCED trial1-2 Surveillance, Epidemiology, and End Results (SEER) program anal… One share of EXAS stock can currently be purchased for approximately $78.59.

exas stock price today

Style is calculated by combining value and growth scores, which are first individually calculated. MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. You can find your newly purchased EXAS stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets. The technique has proven to be very useful for finding positive surprises.

The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.40 billion-$2.40 billion, compared to the consensus revenue estimate of $2.42 billion. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.

EXAS, +0.98% gained more than 7% in premarket trading Wednesday after the company released results from a study of its next-generation Cologuard, a non-invasive colorect… Exact Sciences’ stock is owned by a variety of retail and institutional investors. The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.

Is It Time to Sell EXAS? Shares are down today.

In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Exact Sciences said on Tuesday its next-generation screening test for colon cancer showed 30% lower false positive rate for detecting the disease in a study when compared to trial data on its already …

The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Exact Sciences’ stock was trading at $49.51 at the beginning of 2023. Since then, EXAS shares have increased by 58.7% and is now trading at $78.59. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.

exas stock price today

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI. High-growth stocks tend to represent the technology, healthcare, and communications sectors.

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company’s employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Promising Stocks in Early Cancer Detection

They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. 14 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Exact Sciences in the last twelve months. There are currently 5 hold ratings and 9 buy ratings for the stock.

This site is protected by reCAPTCHA and the Google

Privacy Policy and

Terms of Service apply. We’d like to share more about how we work and what drives our day-to-day business. Compare

EXAS’s historical performance

against its industry peers and the overall market.

The consensus among Wall Street research analysts is that investors should “moderate buy” EXAS shares. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered.

According to 17 analysts, the average rating for EXAS stock is “Buy.” The 12-month stock price forecast is $94.86, which is an increase of 20.70% from the latest price. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Exact Sciences issued an update on its FY 2023 earnings guidance on Wednesday, June, 28th.

These investments are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees trading of commodities when you purchase or sell Alternative Assets. For more information on risks and conflicts of interest, see these disclosures. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. An indication of interest to purchase securities involves no obligation or commitment of any kind.

Please see Open to the Public Investing’s Fee Schedule to learn more. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. None of these entities provide legal, tax, or accounting advice. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy.

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

Not a Wall, But an Obstacle Course: New Findings Reveal Why 45-Year-Olds Are Avoiding Colorectal Cancer Screenings

Both companies have outperformed the market over the past year.

The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account.

This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.

Reports record results, generates positive free cash flow, raises full-year guidance Second -quarter 2023 highlights Total second quarter revenue of $622 million, an increase of 19%, and $617 million … Upgrade to MarketBeat All Access to add more stocks to your watchlist. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.

  • The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers.
  • Exact Sciences issued an update on its FY 2023 earnings guidance on Wednesday, June, 28th.
  • Data may be intentionally delayed pursuant to supplier requirements.
  • Additional information about your broker can be found by clicking here.
  • It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
  • At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors.

69.0% of employees surveyed would recommend working at Exact Sciences to a friend. Shares of Guardant Health Inc. tanked 40% and shares of Exact Sciences Corp. rallied more than 25% in the extended session Thursday after Guardant announced results from a study using its blood test to screen for colorec… Product offerings and availability vary based on jurisdiction. When you see EXAS stock appear in the results, tap it to open up the purchase screen. Below are the latest news stories about EXACT SCIENCES CORP that investors may wish to consider to help them evaluate EXAS as an investment opportunity.

Fox Sued Again: NYC Pension Funds Allege False Election Coverage Exposed Company To Defamation

Data may be intentionally delayed pursuant to supplier requirements. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. Style is an investment factor that has a meaningful impact on investment risk and returns.

Reports record results, raises full-year guidance, accelerates path to positive free cash flow First  quarter highlights Total first quarter revenue of $602 million, an increase of 24%, and $598 milli… BLUE-C study met all endpoints, showing improved cancer sensitivity, https://bigbostrade.com/ specificity, and precancer sensitivity 20,000-participant study reflects racial and ethnic diversity of the U.S. Kevin Conroy, Exact Sciences CEO, joins ‘Fast Money’ to discuss Exact Sciences latest trial results for its colo-rectal cancer tests, Cologuard.

Exact Sciences’s Q3 earnings are confirmed for Thursday, November 2, 2023. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.

To see all exchange delays and terms of use, please see disclaimer. For more insight on analysts targets of EXAS, see our EXAS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page. Dividend yield allows investors, particularly those interested in dividend-paying stocks,

to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Results of three modeling studies demonstrated that non-invasive colorectal cancer screening with Cologuard® is more effective when compared to hypothetical blood-based screening1-3 MADISON, Wis. , Ma…